Tsumura & Co. (TSMRF) Stock Analysis

Tsumura & Co. (TSMRF) Healthcare & Pipeline Overview

Tsumura & Co. is a leading manufacturer of Kampo medicines, leveraging its expertise in traditional Japanese herbal medicine to serve a global market. With a strong focus on Kampo extract intermediates and granular formulations, the company maintains a solid profit margin and dividend yield within the specialty pharmaceutical sector.

What Is the Investment Thesis for TSMRF?

With a P/E ratio of 9.18 and a profit margin of 15.3%, the company demonstrates financial stability. A dividend yield of 3.55% offers investors an attractive income stream. Growth catalysts include increasing global interest in traditional medicine and the potential for expansion into new markets. However, potential risks include regulatory hurdles and competition from other pharmaceutical companies. The company's low beta of -0.07 suggests a relatively low correlation with the broader market, potentially offering downside protection during market downturns. Investors may want to evaluate the company's long-term growth prospects and its ability to maintain its competitive advantage in the evolving healthcare landscape.

Based on FMP financials and quantitative analysis

TSMRF Key Highlights

Market capitalization of $1.73B reflects the company's established position in the Kampo medicine market.

• P/E ratio of 9.18 indicates a potentially undervalued stock compared to its earnings.
• Profit margin of 15.3% demonstrates efficient operations and strong pricing power.
• Gross margin of 47.6% highlights the company's ability to control costs and generate revenue from its products.
• Dividend yield of 3.55% provides an attractive income stream for investors.

Who Are TSMRF's Competitors?

TSMRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are TSMRF's Key Strengths?

Established brand and reputation in Kampo medicine.

• High profit margin and dividend yield.
• Expertise in traditional herbal medicine.
• Global presence and distribution network.

What Are TSMRF's Weaknesses?

Reliance on traditional medicine market, which may have limited growth potential.

• Potential regulatory challenges in different markets.
• Competition from other pharmaceutical companies.
• Limited product diversification beyond Kampo formulations.

What Could Drive TSMRF Stock Higher?

Increasing global interest in traditional medicine and herbal remedies.

• Potential expansion into new geographic markets, such as Europe and North America.
• Development and launch of new Kampo formulations targeting specific health conditions.
• Strengthening partnerships with healthcare providers to integrate Kampo medicine into mainstream healthcare practices.

What Are the Key Risks for TSMRF?

Regulatory challenges and compliance requirements in different markets.

• Increased competition from other pharmaceutical companies and herbal medicine providers.
• Changing consumer preferences and healthcare trends.
• Economic downturns and market volatility.
• Risks associated with trading on the OTC Other tier, including limited financial disclosure and lower liquidity.

What Are the Growth Opportunities for TSMRF?

• Expanding into new geographic markets: Tsumura & Co. has the opportunity to expand its presence in markets with growing interest in traditional medicine, such as Europe and North America. The global herbal medicine market is projected to reach $129.3 billion by 2028, presenting a significant growth opportunity for Tsumura. Successful market entry could drive revenue growth and increase brand recognition.
• Developing new Kampo formulations: Investing in research and development to create new Kampo formulations targeting specific health conditions can drive product innovation and expand Tsumura's product portfolio. The company can leverage its expertise in traditional medicine to develop evidence-based formulations that meet the evolving needs of consumers and healthcare professionals. This could lead to increased sales and market share.
• Strengthening partnerships with healthcare providers: Collaborating with healthcare providers to integrate Kampo medicine into mainstream healthcare practices can increase awareness and acceptance of Tsumura's products. By providing education and training to healthcare professionals, Tsumura can promote the benefits of Kampo medicine and drive adoption. This strategy can enhance the company's credibility and expand its reach to a wider patient population.
• Leveraging e-commerce and digital marketing: Utilizing e-commerce platforms and digital marketing strategies can enhance Tsumura's online presence and reach a broader audience. By creating engaging content and offering convenient online purchasing options, Tsumura can attract new customers and drive online sales. The global e-commerce market is expected to continue growing, providing a significant opportunity for Tsumura to expand its online business.
• Acquiring or partnering with complementary businesses: Tsumura & Co. can explore strategic acquisitions or partnerships with companies in related fields, such as herbal supplement manufacturers or traditional medicine clinics. This can expand Tsumura's product offerings, distribution channels, and customer base. Synergies between Tsumura and its partners can create new growth opportunities and enhance the company's competitive position.

What Are TSMRF's Competitive Advantages?

• Established brand reputation in the Kampo medicine market.
• Proprietary knowledge and expertise in Kampo formulation and manufacturing.
• Strong relationships with raw material suppliers.
• Regulatory approvals and certifications for its products.

What Does TSMRF Do?

Founded in 1893, Tsumura & Co. has evolved into a global pharmaceutical company specializing in Kampo medicines. Originating in Tokyo, Japan, the company's core business revolves around the manufacture and sale of pharmaceutical products, with a particular emphasis on Kampo extract intermediates and granular Kampo formulations. Tsumura is involved in the entire Kampo medicine value chain, from the procurement, selection, processing, and storage of raw material crude drugs to the manufacturing of Kampo powdered extracts and traditional Chinese medicines. The company's product portfolio includes a wide range of Kampo formulations addressing various health conditions. These formulations are sold as pharmaceuticals and food products. Tsumura's commitment to quality and efficacy is reflected in its rigorous manufacturing processes and adherence to regulatory standards. The company's global reach extends to various markets, where it serves healthcare professionals and consumers seeking traditional herbal remedies. Tsumura's competitive positioning is rooted in its long history and expertise in Kampo medicine. The company differentiates itself through its focus on high-quality raw materials, advanced extraction techniques, and evidence-based research to support the efficacy of its products. With a workforce of 4,138 employees, Tsumura continues to innovate and expand its offerings in the Kampo medicine space, while maintaining its commitment to traditional practices and patient well-being.

What Products and Services Does TSMRF Offer?

• Manufactures and sells pharmaceutical products worldwide.
• Offers Kampo extract intermediates.
• Provides granular Kampo formulations.
• Procures, selects, and processes raw material crude drugs.
• Manufactures Kampo powdered extracts.
• Produces traditional Chinese medicines.
• Sells pharmaceuticals and food products.

How Does TSMRF Make Money?

• Procurement and processing of raw materials for Kampo medicines.
• Manufacturing of Kampo extracts and formulations.
• Distribution and sale of pharmaceutical products through various channels.
• Research and development of new Kampo formulations.

What Industry Does TSMRF Operate In?

Tsumura & Co. operates within the specialty and generic drug manufacturing industry, which is experiencing growth driven by an aging global population and increasing demand for healthcare solutions. The market for traditional medicines, including Kampo, is expanding as consumers seek alternative and complementary therapies. The competitive landscape includes both large pharmaceutical companies and smaller specialized firms. Tsumura's focus on Kampo medicine provides a niche market position, but the company must navigate regulatory challenges and compete with other herbal medicine providers.

Who Are TSMRF's Key Customers?

• Healthcare professionals (doctors, pharmacists).
• Patients seeking traditional herbal remedies.
• Distributors and wholesalers of pharmaceutical products.
• Consumers interested in health and wellness products.

Company Profile

Tsumura & Co. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Terukazu Kato. TSMRF has traded publicly since 2013.

Tsumura & Co. Financial Trajectory

Tsumura & Co. (TSMRF) reported $49.34B in revenue for Q1 FY2027, reflecting 3.4% growth compared to the prior quarter. The company recorded net income of $6.41B, with diluted EPS of $86.00. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, TSMRF averaged $101.77 in diluted EPS.

How Tsumura & Co. Is Valued

Tsumura & Co. carries a market capitalization of $1.73B, placing it in the small-cap category.

Return on equity for Tsumura & Co. stands at 9.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.0%, showing how much profit it generates from its asset base. TSMRF trades at a trailing price-to-earnings ratio of 9.18, below the Healthcare sector average of ~21.50x. Its free cash flow yield is -6.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 10.8%, the inverse of the P/E and a quick read on earnings relative to price.

Tsumura & Co.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.37 places it in the grey zone, a middle ground that warrants monitoring.

Tsumura & Co. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 6.0% above estimates on average.

TSMRF Financials

TSMRF Latest News

No recent news available for TSMRF.

TSMRF Analyst Consensus

TSMRF MoonshotScore

Common Questions About TSMRF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources